These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 386308

  • 21. Biochemical aspects of Parkinson's disease.
    Nagatsu T.
    Adv Neurol; 1993; 60():165-74. PubMed ID: 8093575
    [No Abstract] [Full Text] [Related]

  • 22. [Reconsiderations in the treatment of Parkinson's disease with levodopa: some pharmacodynamic evidence].
    Zappia M, Nicoletti A, Muñoz-S D, Tapia-Núñez J.
    Rev Neurol; 1993; 49(1):33-40. PubMed ID: 19557698
    [Abstract] [Full Text] [Related]

  • 23. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
    Hossain MA, Weiner N.
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. The effects of combining carbidopa with levodopa for Parkinson's disease.
    Martin WE, Tolosa ES, Loewenson RB, Lee MC, Resch JA, Baker AB.
    Geriatrics; 1975 Dec; 30(12):39-44. PubMed ID: 1104406
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease.
    Yokochi M.
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S25-30. PubMed ID: 19131038
    [Abstract] [Full Text] [Related]

  • 30. Parkinson's disease and levodopa. A five-year follow-up and review.
    Markham CH, Treciokas LJ, Diamond SG.
    West J Med; 1974 Sep; 121(3):188-206. PubMed ID: 4606887
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
    St-Hilaire M, Landry E, Lévesque D, Rouillard C.
    Neurobiol Dis; 2005 Nov; 20(2):450-60. PubMed ID: 15896973
    [Abstract] [Full Text] [Related]

  • 35. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
    Carlsson T, Carta M, Muñoz A, Mattsson B, Winkler C, Kirik D, Björklund A.
    Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
    [Abstract] [Full Text] [Related]

  • 36. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R, Lees AJ.
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [Abstract] [Full Text] [Related]

  • 37. Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment.
    Hirsch EC.
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S115-20; discussion S120-1. PubMed ID: 10762138
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Levodopa: pharmacology, pharmacokinetics, and pharmacodynamics.
    Juncos JL.
    Neurol Clin; 1992 May; 10(2):487-509. PubMed ID: 1584186
    [Abstract] [Full Text] [Related]

  • 40. Problems of levodopa treatment.
    Horstink MW.
    Clin Neurol Neurosurg; 1984 May; 86(3):196-206. PubMed ID: 6091967
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.